Forte Biosciences Ownership
FBRX Stock | USD 8.30 0.76 10.08% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 1.8 M | Current Value 1.8 M | Avarage Shares Outstanding 10.1 M | Quarterly Volatility 10.3 M |
Forte |
Forte Stock Ownership Analysis
About 80.0% of the company shares are owned by institutional investors. The book value of Forte Biosciences was currently reported as 6.42. The company recorded a loss per share of 20.91. Forte Biosciences last dividend was issued on the 16th of June 2020. The entity had 1:25 split on the 28th of August 2024. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. Forte Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Forte Biosciences call Paul Wagner at 310 618 6994 or check out https://www.fortebiorx.com.Besides selling stocks to institutional investors, Forte Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Forte Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Forte Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Forte Biosciences Quarterly Liabilities And Stockholders Equity |
|
Forte Biosciences Insider Trades History
About 10.0% of Forte Biosciences are currently held by insiders. Unlike Forte Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Forte Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Forte Biosciences' insider trades
Forte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Forte Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forte Biosciences backward and forwards among themselves. Forte Biosciences' institutional investor refers to the entity that pools money to purchase Forte Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Longwood Capital Partners Llc | 2024-12-31 | 18.1 K | Geode Capital Management, Llc | 2024-12-31 | 16.9 K | Blackrock Inc | 2024-12-31 | 6.8 K | Royal Bank Of Canada | 2024-12-31 | 3.8 K | Jpmorgan Chase & Co | 2024-12-31 | 2.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 151 | Group One Trading, Lp | 2024-12-31 | 104 | Tower Research Capital Llc | 2024-12-31 | 100.0 | Comerica Bank | 2024-12-31 | 56.0 | Fred Alger Management, Llc | 2024-12-31 | 1.1 M | Tybourne Capital Management (hk) Ltd | 2024-12-31 | 620 K |
Forte Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forte Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Forte Biosciences Outstanding Bonds
Forte Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Forte Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Forte bonds can be classified according to their maturity, which is the date when Forte Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
FORTUNE BRANDS HOME Corp BondUS34964CAA45 | View | |
US34964CAE66 Corp BondUS34964CAE66 | View | |
FBINUS 45 25 MAR 52 Corp BondUS34964CAG15 | View | |
FBINUS 4 25 MAR 32 Corp BondUS34964CAF32 | View | |
US34960PAD33 Corp BondUS34960PAD33 | View | |
MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
FORTUNE BRANDS INC Corp BondUS349631AG67 | View |
Forte Biosciences Corporate Filings
14th of February 2025 Other Reports | ViewVerify | |
10th of February 2025 Other Reports | ViewVerify | |
7th of February 2025 Other Reports | ViewVerify | |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.